Northwestern Mutual Wealth Management
GALT icon

Northwestern Mutual Wealth Management’s Galectin Therapeutics GALT Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.17K Buy
1,976
+91
+5% +$236 ﹤0.01% 3145
2026
Q1 		$5.26K Buy
1,885
+1,285
+214% +$3.91K ﹤0.01% 3294
2025
Q4 		$2.5K Buy
+600
New +$3.16K ﹤0.01% 3423

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northwestern Mutual Wealth Management's GALT Position: Q2 2026 in Review

Northwestern Mutual Wealth Management increased its Galectin Therapeutics (GALT) stake by 4.8% in Q2 2026, buying an estimated $236 and bringing the position to 1,976 shares worth $9.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3145.

Northwestern Mutual Wealth Management first reported a position in GALT in Q4 2025 and has held it in 3 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Northwestern Mutual Wealth Management held 1,976 shares of Galectin Therapeutics worth $9.17K as of Q2 2026.
  • Northwestern Mutual Wealth Management bought 91 Galectin Therapeutics shares in Q2 2026, an estimated $236.
  • Galectin Therapeutics made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q2 2026, its #3145 holding.
  • Northwestern Mutual Wealth Management first reported a position in Galectin Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.